Please login to the form below

Not currently logged in
Email:
Password:

Sanofi expands biosurgery presence with Pluromed acquisition

Gains access to the US medical device company's blood vessel occlusion gel LeGoo

Sanofi is to acquire US medical device company Pluromed for an undisclosed amount in a deal that will expand its presence in the biosurgery market.

Massachusetts-based Pluromed markets an FDA approved and CE marked gel called LeGoo that provides temporary blood vessel occlusion during surgery, which Sanofi will now commercialise.

“The  acquisition of Pluromed underscores Sanofi's commitment to strengthen its Biosurgery portfolio,”  said Alison Lawton,  senior vice president and general manager, Sanofi Biosurgery.

“LeGoo is a breakthrough technology with the potential to change the paradigm of vascular and cardiovascular surgical procedures, by providing fast, temporary control of blood flow while avoiding vessel trauma associated with standard of care.”

Pluromed also has a proprietary polymer technology, called  Rapid  Transition Polymers (RTP), which uses injectable plugs to improve the safety, efficacy and economics of medical interventions.

"The synergies between our companies were clear from the beginning,”  said Pluromed's CEO Jean-Marie Vogel. “We are confident that Sanofi has the  expertise and resources necessary to bring LeGoo to market and drive adoption."

LeGoo is a thermo-sensitive biocompatible and non-toxic liquid gel that forms a plug when injected into a blood vessel to temporarily stop blood flow.

This allows surgeons to temporarily control bleeding without clamps or snares, which can injure delicate blood vessels. The plug then dissolves rapidly via cooling or spontaneously after several  minutes.

Sanofi's Biosurgery business unit currently markets products for osteoarthritis relief, adhesion prevention, cartilage repair, and severe burn treatment.

The company is also working on MACI (Matrix-induced Autologous Chondrocyte Implantation), a cell-based treatment for articular cartilage defects that is in phase III clinical trials.

21st March 2012

Share

Featured jobs

Subscribe to our email news alerts

PMHub

Add my company
IGNIFI

We’re IGNIFI. An independent creative agency, we help spark and sustain successful brands for some of the biggest names in...

Latest intelligence

patients
Retaining reader value in plain language summaries of clinical studies
Balancing the risk of misinterpretation with the public’s ability to understand simplified plain-language summaries...
Can we talk about the ego-bias and chemicals influencing your target audience’s behaviour?
Over the Summer, the Page & Page team became fascinated by two books on this very subject. Two books from one author, Dean Burnett, an eminent neuroscientist, lecturing at Cardiff...
Paris
Making Europe a leader in bioscience: boosting trust and opening minds
A vision of Paris as Europe's leading hub for life sciences innovation...

Infographics